| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net sales | 177,800 | 175,000 | 167,500 | 170,400 |
| Cost of products sold | 91,800 | 82,900 | 77,700 | 77,500 |
| Gross profit | 86,000 | 92,100 | 89,800 | 92,900 |
| Research and development | 6,000 | 5,800 | 5,400 | 7,200 |
| Selling and general expenses | 77,600 | 83,500 | 75,700 | 74,300 |
| Goodwill impairment | 0 | 77,000 | - | - |
| Other expense (income), net | -2,300 | -300 | 1,600 | 600 |
| Operating income (loss) | 100 | -74,500 | 10,300 | 12,000 |
| Interest income | 500 | 600 | 1,500 | 700 |
| Interest expense | 1,800 | 2,000 | 2,100 | 3,200 |
| (loss) income before income taxes | -1,200 | -75,900 | 9,700 | 9,500 |
| Income tax provision | 200 | 900 | 3,100 | 3,600 |
| (loss) income from continuing operations | -1,400 | -76,800 | 6,600 | 5,900 |
| Loss from discontinued operations, net of tax | 0 | 0 | - | -1,600 |
| Net (loss) income | -1,400 | -76,800 | 6,600 | 4,300 |
| Basic (loss) earnings per share (in dollars per share) | -0.03 | -1.66 | 0.14 | 0.1 |
| Basic weighted average shares outstanding (in shares) | 46,400,000 | 46,300,000 | 46,100,000 | 46,000,000 |
| Diluted (loss) earnings per share (in dollars per share) | -0.03 | -1.66 | 0.14 | 0.09 |
| Diluted weighted average shares outstanding (in shares) | 46,400,000 | 46,300,000 | 46,800,000 | 46,600,000 |
AVANOS MEDICAL, INC. (AVNS)
AVANOS MEDICAL, INC. (AVNS)